Alzinova AB (publ)
Interim report Q1 2024

We will make it possible for Alzheimer's patients to live an independent and active life.

Summary of the period January – March 2024

Highlights – first quarter

Positive and strong data with ALZ-101
- Primary and secondary endpoints met in part A of the phase 1b study

Part A2 of the phase 1b study was started
– Regulatory approval to evaluate higher dose with ALZ-101

Positive change on biomarkers was demonstrated
– In-depth analysis of part A demonstrates positive change on biomarkers.

Key figures from the period

Three months, January – March 2024

- Net sales amounted to SEK 30 thousand (0).
- Loss after financial items amounted to SEK -4,963 thousand (-4,272).
- Average number of shares during the period before dilution amounted to 44,531,265 (32,419,034).
- Average number of shares during the period after dilution amounted to 44,531,265 (45,545,811).
- Earnings per share before dilution amounted to SEK -0.11 (-0.13).
- Earnings per share after dilution amounted to SEK -0.11 (-0.09).

Amounts in brackets: Corresponding period in previous year.
"the Company" or **"Alzinova"** refers to Alzinova AB with corporate identity number: 556861-8168.

Events during the first quarter 2024

- Alzinova announced the full analysis of the data from part A of the phase 1b clinical trial, with the vaccine candidate ALZ-101. The analysis confirmed the positive results previously reported. Given the favourable safety profile, the Company applied for an extension to the study to evaluate a higher dose level. The extension was included to optimise the design of the upcoming phase 2 study.
- In February, the Company received regulatory approval to evaluate a higher dose of the vaccine candidate ALZ-101 in the ongoing phase 1b study.
- Erik Kullgren was appointed interim CFO and the process of recruiting a permanent CFO is ongoing.

Events after the end of the first quarter 2024

- All patients in the extension part (part B) of the phase 1b study had been dosed with the last dose of the Alzheimer's disease vaccine candidate ALZ-101.
- An in-depth analysis of data from part A of Alzinova's phase 1b study with the vaccine candidate ALZ-101 was conducted in April. The analysis indicated that patients with higher antibody levels after vaccination had a positive effect on biomarkers associated with Alzheimer's disease.
- Alzinova's CEO, Kristina Torfgård, informed the Board of her wish to step down as CEO of the Company.
- Alzinova's Board of Directors decided, with the support of authorisation from the Annual General Meeting 2023, on a rights issue of shares of approximately SEK 34.4 million.
- Notice of the Annual General Meeting to be held on 29 May 2024 at 13:00 at Chalmersska Huset in Gothenburg was published.
- Alzinova's annual report for 2023 was published.
- The Company announced planned presentations at both Swedish and international investor meetings and partnering meetings during the spring.
- The first patient was dosed in the Company's high-dose part of the phase 1b study.

A word from the CEO

I would like to start by highlighting the most important thing that has happened in the company, namely the excellent results we obtained from the full analysis of the data from the first part of the phase 1b clinical trial, with the vaccine candidate ALZ-101. With these strong data from the phase 1b trial and with upcoming important milestones, I am convinced that the company has an exciting future with the goal of being able to offer a therapeutic vaccine against Alzheimer's disease through strategic partnering.

ALZ-101 vaccine candidate - results & biomarkers

In January, we received impressive results from the full analysis of the data from part A of the phase 1b clinical study. The primary and secondary objectives of the study were met, i.e. ALZ-101 has a favourable safety and tolerability profile. In addition, the results showed a positive response to the vaccine with a high frequency of immune responses. The excellent safety profile allows for the evaluation of a higher dose level which started in the first quarter. In the new part, six additional patients will be treated with a higher dose for 16 weeks. The addition is made to optimise the design of the upcoming phase 2 study.

We reached another important milestone in the first quarter when all patients in the extension part (part B) received their fourth and final dose. For phase 2, an analysis of the data is planned for the fall of 2024, before part B is fully reported.

An in-depth analysis of the data from part A has also been conducted and from these new analyses we see very promising results. The results, indicate that there are patients who already, after 16 weeks of treatment with our vaccine candidate respond positively with vaccine-induced changes to biomarkers associated with Alzheimer's disease. Seeing results this early is fantastic and we now look forward to the upcoming evaluation of data from longer treatment time and higher dose with ALZ-101. The results are also important for our partner dialogues and preparations for the phase 2 study.

The new documentation shows that ALZ-101 has the potential to be a better treatment than competing products, i.e. "best in class".

Focus on partnering agreements to accelerate the development of ALZ-101

From a strategic perspective, we have been working diligently to evaluate potential partners. We focus on their pipeline capacity, business flow and ability to acquire our vaccine candidate as a project for further development and then commercialisation. A priority area for 2024 is to sign a partnering agreement to accelerate the further clinical and commercial development of ALZ-101. The recently announced major licensing deal between the biopharmaceutical company AC Immune and the Japanese pharmaceutical company Takeda Pharmaceuticals for the Alzheimer's vaccine candidate ACI-24.060 reinforces this strategy and can be seen as a benchmark for the enormous potential value and demand that exists for a vaccine treatment for Alzheimer's. The main difference between AC Immune's candidate and our vaccine candidate ALZ-101 is that ours is more specific, targeting just the toxic oligomers. This, together with the fact that we have already proven at an early stage of development that our candidate has strong potential, sets us apart in the market.

With promising results from part A of the phase 1b clinical trial, the intention is to continue the clinical development of ALZ-101 in a phase 2 study, a study that we believe can best be financed through a partnership. The proposed share issue aims to advance the development of ALZ-101 and thus strengthen the company for a partnership, which can provide the best possible terms for shareholders in such a contract negotiation.

With strong data from the phase 1b study and with upcoming important milestones, I am convinced that the company has an exciting future with the goal of offering a therapeutic vaccine for Alzheimer's disease through strategic partnering.

It has been a fantastic journey, and I am very proud of what we at Alzinova have achieved during my time as CEO. I have been involved in building the company during an important part of the company's development and with the great data we have obtained in the phase 1b clinical trial, as well as ongoing strategic partnering discussions, we have come to a point where I think the company is now ready for a change of CEO. I look forward to following the company as an engaged shareholder in the future.

Kristina Torfgård,
CEO of Alzinova AB

Through strategic partnering, I am confident that Alzinova will be able to offer a therapeutic vaccine for Alzheimer's disease



About Alzinova

Alzinova AB is a Swedish biopharmaceutical Company specializing in the treatment of Alzheimer's disease. The Company's patented AβCC peptide technology™ enables the development of disease-modifying therapies with the potential to selectively neutralize the toxic accumulations of the peptide, so-called oligomers, which are central to the onset and progression of Alzheimer's disease. With this technology, we can develop effective treatments that have a favorable profile with a lower risk of side effects compared to other treatments. Promising preclinical results have been obtained following a study on brain extracts from deceased Alzheimer's patients, demonstrating evidence of the mechanism of these actions.

Alzinova's primary focus is the development of a vaccine that is being developed as a long-acting treatment for Alzheimer's disease. The vaccine candidate ALZ-101 is in clinical development with a phase 1b study in Alzheimer's patients started Q3 2021. Based on positive interim data from part A, the Company has initiated an extension part, part B, of the study, which is expected to be completed in early 2025.

Part A of the study was completed at the end of 2023 with positive results where ALZ-101 shows good safety and tolerability as well as a clear immunological response. The results from the complete analysis from the A part open up the possibility of evaluating another higher dose. Alzinova has therefore initiated dosing an additional cohort with 400 µg of ALZ-101, which will be implemented in 2024. Overall, the results of preclinical and clinical studies mean that Alzinova has the potential to develop a treatment that is better than other treatments currently on the market.

Based on the same AβCC peptide technology, the Company is also developing the ALZ-201 antibody, which is currently in preclinical development. The project portfolio for the development of disease-modifying treatments is being broadened as the Company prepares the antibody for clinical development. Alzinova was founded by researchers who have worked at the MIVAC research center at the University of Gothenburg, and by GU Ventures AB.

Alzinova's unique solution

- ✓ Targeted treatment that specifically targets and neutralizes the toxic peptides (so-called oligomers) that are central to the onset and development of Alzheimer's disease.
- ✓ A vaccine that stimulates the body to produce its own antibodies against oligomers (ALZ-101).
- ✓ Specific treatment that is predicted to have good efficacy and reduces the risk of serious side effects.
- ✓ Fast, effective and uncomplicated vaccination without long and expensive hospital stays.
- ✓ Can start treatment early to prevent progression.
- ✓ Monoclonal antibody (ALZ-201) that neutralizes the toxic oligomers and can be used as a stand-alone or as a complement to the vaccine (ALZ-101).

Other actors

- Are developing treatments that target larger accumulations of amyloid-beta, so-called plaques in the brain, which are believed to contain both toxic and harmless protein.
- Non-specific treatments which are not specifically targeting and neutralizing the toxic oligomers.
- Often complicated drug treatments that require expensive hospital care.
- Targeting plaque is unlikely to be sufficiently effective and may result in serious side effects.





About Alzheimer

In Alzheimer's disease, the nerve cells in the brain are damaged by abnormal protein deposits that mainly consist of amyloid-beta 42 (Aβ42), a type of small protein that also occurs in a healthy brain. When the Aβ42 molecule clumps together, stable accumulations are formed in the brain, plaques, but also so-called oligomers.

Oligomers differ structurally from the plaque and, unlike the plaque, are highly toxic to brain cells. They damage important functions that make the contact surfaces between the nerve cells, the synapses, stop working normally. Synapses are the places in the brain where electrical and chemical signals are transmitted from one nerve cell to another, and their function is critical to our ability to remember, react, think and act. Eventually the nerve cell dies.

The disease first affects the parts of the brain that handle short-term memory, but eventually the disease spreads over the entire brain and the patient finds it increasingly difficult to carry out daily tasks. In the end, the patient cannot manage on their own, but requires care and continuous monitoring.

Alzheimer's is a disease that basically anyone can get, and which is strongly age-dependent. Over 95% of all cases affect those over the age of 65, and in these cases there is not a strong genetic component driving the disease. The disease then increases sharply in prevalence in the 75-80 age range.

Business model

Alzinova's business model is to drive projects into clinical development with the aim of documenting that the drug candidates are safe and well tolerated as well as demonstrating proof-of-concept, i.e. that they exhibit efficacy in patients with Alzheimer's disease. Based on positive clinical data, the Company has identified several potential strategic partners who have the resources and in-house expertise to conduct the studies needed for registration and commercialisation. This can be done through out-licensing with a partnership where the Company jointly brings the drug to the market with the collaboration partner, or or by selling the drug candidate for further development.

Out-licensing

A common alternative for development companies like Alzinova is to out-license projects to one or more pharmaceutical companies. Either these can get exclusivity in a limited market, and you agree with several partners to cover the market globally, or you have a global partner who takes the drug to the entire market. A typical arrangement for out-licensing is initial compensation and then future installments linked to pre-defined milestones during further development, the regulatory process and commercialization with high revenues linked to future drug sales.

The Company has so far taken several important steps towards out-licensing and commercialization. The data shows "best-in-class" potential, which is very attractive for partnering. With positive results in the Company's two drug projects, ALZ-101 and ALZ-201, there are several options. One is to out-license the ALZ-101 vaccine to a major pharmaceutical company, and another option is for Alzinova to take ALZ-101 through phase 2 and then out-license it to a partner. For the antibody ALZ-201, this could be out-licensed immediately during the preclinical phase, or alternatively after phase 1b studies. The Company's focus going forward is on business development with several ongoing dialogues in parallel with clinical development of the project portfolio.

Market

Every year around 10 million people in the world become ill with some form of dementia, of which Alzheimer's disease accounts for around 60-70 %. Today, it is estimated that there are approximately 55 million patients with dementia in the world, but it is difficult to diagnose dementia today at early stages of disease. Therefore, it is expected that this figure is significantly higher. In addition, this number is expected to increase to more than 130 million by 2050. It is estimated that more than 30 million people in the world today have Alzheimer's disease and the number is expected to triple by 2050[1].

The societal costs of dementia diseases are currently estimated at $1,300 billion annually[2]. The drug cost of Alzheimer's medications, which are symptom relief alone, amounts to approximately $6 billion annually. While the first disease-modifying drugs has recently been approved in the United States, Japan and China there is still a very long way to go to truly treat and prevent the progression of Alzheimer's disease.

The sales and revenue potential of a new effective disease-modifying drug is therefore significant even if it would only have an initially limited market share. By 2026, drugs for Alzheimer's disease are expected to be represented among 2 out of 7 expected top sellers (pharmaceutical companies), with an expected annual turnover of USD 1.7-4.5 billion[3]. The reason why the initial sales estimates are relatively low is that there have been no good medical alternatives. With effective treatment options coming to the market, such as Alzinova's drug, the Company estimates that annual sales can be multiplied several times compared to today.

The research firm Global Data estimates that annual sales for disease-modifying drugs for Alzheimer's disease will reach roughly $13 billion by 2028 in the largest markets: the United States, Germany, France, the United Kingdom, Italy, Spain, Japan, China, and India. An approved disease-modifying treatment for Alzheimer's disease has the potential to generate peak annual sales in excess of USD 10 billion[4].

1) World Health Organization (WHO) – Facts about Dementia, March 2023
2) World Alzheimer's Report, 2021.
3) Drugs to watch report, 2022.
4) US, Germany, France, UK, Italy, Spain, Japan, China. GlobalData, Pharma, June 7, 2023.

Alzinova's competitive advantages



Based on statistics from Statistics Sweden (SCB) about the Swedish healthcare system, and that the two treatments have equivalent clinical efficacy, total treatment duration and drug cost.

Alzinova is developing a vaccine candidate to treat Alzheimer's disease. The vaccine, unlike other treatments such as antibodies, is expected to require only a few doses a year rather than as often as every two weeks. In addition, it can be given to patients in a very time-efficient way through a simple injection in primary care or at home by a nurse. Other treatments are time-consuming and require hospital care.

To treat patients with therapeutic antibodies, this sharply increase societal costs, resulting in fewer patients being treated with an antibody treatment. With Alzinova's vaccine, compared to antibody treatment, healthcare and societal costs can be reduced, which creates the opportunity for more people to receive treatment.

Investment highlights

Alzinova's lead candidate, ALZ-101, is a therapeutic vaccine to treat Alzheimer's disease. Positive results from part A of the ongoing study demonstrate good safety and tolerability and a clear immunological response.

Based on the same technology, Alzinova is also developing a monoclonal antibody, ALZ-201, as a complementary treatment to the vaccine to combat Alzheimer's disease.

Data show that the unique specificity of Alzinova's vaccine (ALZ-101) and monoclonal antibody (ALZ-201) provides "best-in-class" potential with a more favorable side effect profile compared to other treatments.

Positive feedback from the FDA and EMA as well as other ongoing activities for the next clinical development phase, together with strong IP, make Alzinova's candidates attractive for strategic partnerships.

Alzinova's goal is to enable Alzheimer's patients to live an independent and active life.

Financial information

Corporate structure and shareholding
Alzinova has no subsidiaries and is not part of any group. Neither does the Company hold any shares.

Financial development
During the period January - March, the Company has continued to invest in the further development of ALZ-101, which is in the final phase of the phase 1b study, where an open extension part and a high dose part also have been initiated. The Company is preparing and investing for clinical phase 2. The Company has also started preparations for clinical studies of the antibody ALZ-201, with the goal of treating and also preventing the progression of Alzheimer's disease.

During the first quarter, the Company received a grant from Vinnova of SEK 30 thousand for the application for possible grant-based project financing.

The Company's total costs during the first quarter of 2024 amounted to SEK 7,817 (8,944) thousand. The largest part of the period's costs, SEK 2,823 (4,672) thousand, related to research and development costs (R&D) and includes costs for preparations for the production of drug substance before the start of the upcoming clinical phase 2 study. The higher level of costs regarding R&D during Q1 2023 mainly related to the ongoing phase 1b clinical study. The Company's R&D costs have been capitalized in the balance sheet. Personnel costs have also increased during the period and amounted to SEK 2,586 (1,953) thousand. The increased costs are due to the growing organization.

The cash flow from operating activities during the first quarter of the year amounted to SEK -6,196 (-4,678) thousand. The difference in cash flow compared to the previous year is mainly due to a lower proportion of capitalized development costs and a reduction of the Company's operating liabilities during the period. The cash flow from investment activities consists of expenses for ongoing capitalized R&D costs during Q1 amounted to SEK -2,823 (-4,672) thousand. The cash flow from financing activities during the period amounted to SEK 0 (0) thousand.

Financial position
At the end of the period, the Company's equity amounted to approximately SEK 108,895 (101,262) thousand with an equity ratio of 93 % (95%), and total cash balances amounted to approximately SEK 13,007 (22,688) thousand.

On April 26, the Company's board decided to carry out a rights issue of shares which, if fully subscribed, can give the Company a capital injection of SEK 34.4 million before issue costs. The issue is guaranteed by subscription bonds and guarantee commitments to 100 %. During the first quarter of 2024, the Company has also received a loan promise on market terms of SEK 5 million from one of the Company's major owners, Maida Vale Capital AB. The decided rights issue together with the loan promise obtained, gives the Company the conditions to continue the clinical development.

Risk factors
A detailed assessment of the Company's uncertainty factors was included in the Annual Report 2023.

Auditor's review
This report has not been reviewed by the Company's auditors.

Policies for the preparation of the interim financial report
The interim financial report is prepared in accordance with the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3).

The Board of Directors and the Chief Executive Officer hereby confirm that this interim report provides a true and fair view of the Company's operations, financial position and earnings, and describes significant risks and uncertain factors the Company is facing.

Mölndal, May 28, 2024
Alzinova AB (publ)

Income statement

(TSEK)	Jan-Mar 2024 3 months	Jan-Mar 2023 3 months	Jan-Dec 2023 12 months
Net sales	30	-	270
Own work capitalized	2,823	4,672	19,604
	2,853	**4,672**	**19,874**
Operating expenses			
Other external expenses	-5,231	-6,991	-27,097
Personnel expenses	-2,586	-1,953	-9,299
Operating result	**-4,964**	**-4,272**	**-16,522**
Result from financial items			
Interest income	1	0	140
Interest expenses	-	0	-98
Result after financial items	**-4,963**	**-4,272**	**-16,480**
Result before tax	**-4,963**	**-4,272**	**-16,480**
Result for the period	**-4,963**	**-4,272**	**-16,480**

Balance sheet

(TSEK)	31 Mar 2024	31 Mar 2023	31 Dec 2023
ASSETS			
Fixed assets			
Intangible assets			
Capitalized expenditure for development work	99,076	81,321	96,253
Patent	1,632	1,632	1,632
	100,708	**82,953**	**97,885**
Total fixed assets	**100,708**	**82,953**	**97,885**
Current assets			
Short term receivables			
Tax receivables	159	320	257
Other receivables	333	534	378
Prepaid expenses and accrued income	2,860	572	2,643
	3,352	**1,425**	**3,278**
Cash and cash receivables	**13,007**	**22,688**	**22,026**
Total current assets	**16,360**	**24,114**	**25,304**
TOTAL ASSETS	**117,068**	**107,067**	**123,189**
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital	11,712	8,526	11,712
Fund for development costs	97,013	79,258	94,190
	108,725	**87,784**	**105,902**
Unrestricted equity			
Share premium	166,264	144,645	166,264
Retained result	-161,131	-126,895	-141,828
Results for the year/period	-4,963	-4,272	-16,480
	170	**13,478**	**7,956**
Total equity	**108,895**	**101,262**	**113,858**
Long term liabilities			
Other long term liabilities	800	800	800
	800	**800**	**800**
Current liabilities			
Accounts payable	2,259	2,165	2,493
Other current liabilities	3,248	654	3,413
Accrued expenses and prepaid income	1,866	2,185	2,625
	7,373	**5,005**	**8,531**
TOTAL EQUITY AND LIABILITIES	**117,068**	**107,067**	**123,189**

Change in equity, condensed

(TSEK) Jan-Mar 2024 3 months	Share Capital	Fund for development costs	Share premium	Retained result incl. result for the year	Total equity
At the beginning of the period	**11,712**	**94,190**	**166,264**	**-158,308**	**113,858**
Transfer within equity		2,823		-2,823	0
Net result for the period				-4,963	-4,963
At the end of the period	**11,712**	**97,013**	**166,264**	**-166,094**	**108,895**

(TSEK) Jan-Mar 2023 3 months	Share Capital	Fund for development costs	Share premium	Retained result incl. result for the year	Total equity
At the beginning of the period	**8,526**	**74,586**	**144,645**	**-122,223**	**105,533**
Transfer within equity		4,672		-4,672	
Net result for the period				-4,272	-4,272
At the end of the period	**8,526**	**79,258**	**144,645**	**-131,167**	**101,262**

(TSEK) Jan-Dec 2023 12 months	Share Capital	Fund for development costs	Share premium	Retained result incl. result for the year	Total equity
At the beginning of the period	**8,526**	**74,586**	**144,645**	**-122,224**	**105,533**
Share issue	3,186		23,098		26,284
Transaction costs share issue			-1,479		-1,479
Transfer within equity		19,604		-19,604	0
Net result for the period				-16,480	-16,480
At the end of the period	**11,712**	**94,190**	**166,264**	**-158,308**	**113,858**

Cash flow statement, condensed

(TSEK)	Jan-Mar 2024 3 months	Jan-Mar 2023 3 months	Jan-Dec 2023 12 months
Operating activities			
Result after financial items	-4,963	-4,272	-16,480
Cash flow from operating activities before change in working capital	**-4,963**	**-4,272**	**-16,480**
Cash flow from change in working capital			
Increase (-)/Decrease (+) in operating receivables	-75	-123	-1,976
Increase (+)/Decrease (-) in operating liabilities	1,158	-283	3,243
Cash flow from operating activities	**-1,158**	**-4,678**	**-15,213**
Investing activities			
Acquisition of intangible fixed assets	-2,823	-4,672	-19,604
Cash flow from investing activities	**-2,823**	**-4,672**	**-19,604**
Financing activities			
Share issue	-	-	26,284
Transaction costs share issue	-	-	-1,479
Cash flow from financing activities	**0**	**0**	**24,805**
Cash flow for the period	**-9,019**	**-9,350**	**-10,012**
Cash and cash equivalents at the beginning of the period	**22,026**	**32,038**	**32,038**
Cash and cash equivalents at the end of the period	**13,007**	**22,688**	**22,026**

The share

Alzinova's share was listed on the Spotlight Stock Market (formerly Aktietorget) on November 25, 2015. As of March 11, 2019, the Company is listed on the Nasdaq First North Growth Market in Stockholm. There is one class of shares in the Company. The share entitles to one (1) vote per share. Each share carries an equal right to a share in the Company's assets and results. As of March 31, 2024, the number of shares in Alzinova amounted to 44,531,265 (32,419,034 as of March 31, 2024).

Share-based incentive programs

Currently there are no long-term share-based incentive programs in the Company.

Largest owners per March 28, 2024

Owner	Number of shares	Capital %
Maida Vale Capital AB	6,748,920	15.16%
Försäkrings AB Avanza pension	3,231,550	7.26 %
Nordnet Pensionsförsäkring AB	1,643,775	3.69%
Patrik Ahlvin	1,004,750	2.26%
Sara Gjertz	753,015	1.69%
MIVAC Development AB	711,787	1.60%
Özlem Erdogdu Gül	709,630	1.59%
MGC Capital Ltd	604,171	1.36%
Moll Invest AB	600,080	1.35%
Ålandsbanken, for owner	528,819	1.18%
Total 10 largest shareholders	**16,536,497**	**37.13%**
Total other shareholders	27,994,768	62.87%
Total all shareholders	**44,531,265**	**100.00%**

Financial calendar

Annual general meeting 2024	29 May 2024
Interim report 2, 2024	22 August 2024
Interim report 3, 2024	14 November 2024
Year-end report, 2024	27 February 2025

Financial reports are available on the Company's website www.alzinova.com as of the date of publication.

For further information, please contact:

Kristina Torfgård, CEO, kristina.torfgard@alzinova.com, telephone +46 708 467975
Erik Kullgren, interim CFO, erik.kullgren@alzinova.com, telephone +46 705 850859
or mail directly to info@alzinova.com

Glossary, definitions and abbreviations

Aβ42 - amyloid-beta 42	A peptide (part of a protein) produced by the body that can aggregate in the brain and cause Alzheimer's disease
"Best-in-class"	A product that is considered superior to other competitors in its class, can be compared to 'first-in-class', which refers to being first to market with a product
Biomarker	A measurable indicator of a state of disease
Clinical studies	A study evaluating a medicine, conducted in humans
Disease-modifying treatment	Treatment that targets the underlying cause of the disease
EMA	European Medicines Agency
FDA	The United States Food and Drug Administration
R&D	Abbreviation for research and development.
IP	Intellectual properties, for example patents
Monoclonal antibody	A type of antibody produced by a single clone of cells
Oligomers	Proteins or peptides, clumped together, used to designate soluble peptide clumps
Peptide	Part of a protein (a small chain of amino acids too small to be classified)
Plaque	Local accumulation of clumped insoluble protein, in Alzheimer's mainly consisting of the peptide Abeta42
Tolerability	The degree of side effects from a medicine that can be tolerated by a patient

Alzinova AB (publ)

Alzinova AB is a Swedish clinical-stage biopharma Company specializing in the treatment of Alzheimer's disease, which focuses on targeting toxic amyloid-beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide™ technology makes it possible to develop disease-modifying treatments that accurately target the toxic amyloid-beta oligomers that are central to the onset and progression of the disease. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases. It is estimated that more than 30 million people in the world today have Alzheimer's disease and the number is expected to triple by 2050. Based on the same technology, the Company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The Company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com

Alzinova AB
Pepparedsleden 1, SE-431 83,
Mölndal, Sweden

alzinova